Trademark: 97315865
Word
TORQUE
Status
Pending
Status Code
654
Status Date
Wednesday, November 15, 2023
Serial Number
97315865
Mark Type
4000
Filing Date
Wednesday, March 16, 2022

Trademark Owner History

Classifications
5 Pharmaceutical preparations for use in gene therapy; biological preparations for use in gene therapy; biological and pharmaceutical preparations, both comprised of therapeutic nucleic acids, namely, RNA, for the treatment and prevention of genetic diseases and disorders, genomic diseases and disorders, neurological diseases and disorders, cardiological diseases and disorders, musculoskeletal diseases and disorders, cancer, infectious diseases, and immune system related diseases and disorders, metabolic diseases and disorders, hematological diseases and disorders, reproductive diseases and disorders, gynecological diseases and disorders, inflammatory diseases and disorders, respiratory diseases and disorders, gastroenterological diseases and disorders, ophthalmological diseases and disorders, and dermatological diseases and disorders; pharmaceutical preparations for treating metabolic diseases and disorders, hematological diseases and disorders, reproductive diseases and disorders, gynecological diseases and disorders, inflammatory diseases and disorders, respiratory diseases and disorders, gastroenterological diseases and disorders, ophthalmological diseases and disorders, and dermatological diseases and disorders, metabolic diseases and disorders, hematological diseases and disorders, reproductive diseases and disorders, gynecological diseases and disorders, inflammatory diseases and disorders, respiratory diseases and disorders, gastroenterological diseases and disorders, ophthalmological diseases and disorders, and dermatological diseases and disorders
42 Testing, inspection, research, and development of pharmaceutical preparations and biological preparations for gene therapy; Pharmaceutical research and development in the field of gene therapy; Biological research and development in the field of gene therapy; consulting services in the fields of biotechnology, pharmaceutical research and development, and in the field of genetic science; custom design and development of biochemical reagents, namely, for use in the synthesis for others of clinical medical reagents for use in gene therapy; development of pharmaceutical preparations for use in gene therapy and gene delivery technology; development of products being genetic therapies; scientific research in the field of genetic engineering, biotechnology research services, and research and development of new products in the field of gene therapeutics and research tools; research and development in the biotechnology field; scientific and medical research and development in the fields of genetic diseases and disorders, genomic diseases and disorders, neurological diseases and disorders, cardiological diseases and disorders, musculoskeletal diseases and disorders, cancer, infectious diseases, and immune system related diseases and disorders, metabolic diseases and disorders, hematological diseases and disorders, reproductive diseases and disorders, gynecological diseases and disorders, inflammatory diseases and disorders, respiratory diseases and disorders, gastroenterological diseases and disorders, ophthalmological diseases and disorders, and dermatological diseases and disorders of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, infectious, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, urological, and viral diseases and disorders and complications associated therewith; scientific research and product development services for others in the pharmaceutical, biotechnology, medical and agriculture fields; testing, inspection, research, or development of pharmaceutical preparations for gene therapy and gene delivery technology; biomedical research and development, scientific research and development, pharmaceutical research and development and product development services in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; product development in the fields of genetic therapies, gene delivery technologies, and effectors to regulate, modulate, and characterize disease states; conducting clinical trials for others in the field of gene therapy design and delivery; biomedical research in the field of gene therapy design and delivery; gene therapy design and development of gene therapy delivery through use of biochemical assays; biomedical research and development, scientific research and development, pharmaceutical research and development and product development in the fields of genetic diseases and disorders, genomic diseases and disorders, neurological diseases and disorders, cardiological diseases and disorders, musculoskeletal diseases and disorders, cancer, infectious diseases, and immune system related diseases and disorders, metabolic diseases and disorders, hematological diseases and disorders, reproductive diseases and disorders, gynecological diseases and disorders, inflammatory diseases and disorders, respiratory diseases and disorders, gastroenterological diseases and disorders, ophthalmological diseases and disorders, and dermatological diseases and disorders autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, infectious, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, urological, and viral diseases and disorders; medical research services, namely, scientific research in the fields of genetic engineering and gene therapy services

Trademark Events
Nov 15, 2023
Report Completed Suspension Check Case Still Suspended
May 2, 2023
Notification Of Letter Of Suspension E-Mailed
May 2, 2023
Letter Of Suspension E-Mailed
May 2, 2023
Suspension Letter Written
Mar 28, 2023
Teas/Email Correspondence Entered
Mar 27, 2023
Correspondence Received In Law Office
Mar 27, 2023
Teas Response To Office Action Received
Dec 30, 2022
Notification Of Non-Final Action E-Mailed
Dec 30, 2022
Non-Final Action E-Mailed
Dec 30, 2022
Non-Final Action Written
Dec 27, 2022
Assigned To Examiner
Mar 22, 2022
New Application Office Supplied Data Entered
Mar 19, 2022
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24